301015 百洋医药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,143,9242.65%7,563,9037,509,6187,051,5675,879,323
减:营业总成本5,252,7180.02%6,702,0486,832,0166,502,5505,501,546
    其中:营业成本3,949,548-1.88%5,296,6225,424,8745,279,7244,406,003
               财务费用57,06221.38%55,83248,38561,34055,294
               资产减值损失(8,591)-258.39%1,851(1,160)2,596(9,312)
公允价值变动收益(6,135)58.37%616(10,750)5,8744,210
投资收益37,981184.07%43,0111,8773,9004,630
    其中:对联营企业和合营企业的投资收益36,872175.56%18,90715,60117,18210,645
营业利润911,47020.42%888,104674,258561,482368,002
利润总额907,91719.96%873,578668,550565,418370,887
减:所得税费用217,34119.61%233,694178,709150,40393,663
净利润690,57620.08%639,883489,841415,016277,225
减:非控股权益49,57969.77%(16,422)(16,757)(6,626)4,514
股东净利润640,99717.42%656,306506,598421,642272,711

市场价值指针
每股收益 (元) *1.22017.31%1.2500.9600.8500.580
每股派息 (元) *----0.7620.7620.667--
每股净资产 (元) *4.206-8.29%4.8874.3844.1073.120
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容